Is Eli Lilly Stock a Buy? Here's What the Market Isn't Pricing in Yet

finance.yahoo.com/news/eli-lilly-stock-buy-heres-124500786.html

In this article:
Key Points
-
Eli Lilly's obesity drugs delivered 38% revenue growth in the second quarter; but its oral GLP-1 candidate fell short, achieving only 12.4% weight loss.
-
Viking Therapeutics' dual-formulation obesity program could capture the most profitable patient segment…

This story appeared on finance.yahoo.com, 2025-08-16 12:45:00.
The Entire Business World on a Single Page. Free to Use →